Pharmacopeia Inc

Pharmacopeia — Investor Day (November 2007)

22 slides from Pharmacopeia's investor day presentation, Nov 14, 2007

  1. Slide 1: Internal Clinical Development Programs

    Slide 1: Internal Clinical Development Programs

    Internal Clinical Development Programs René Belder November 14, 2007

  2. Slide 2: PS433540 Dual Acting Receptor Antagonist (DARA)

    Slide 2: PS433540 Dual Acting Receptor Antagonist (DARA)

    PS433540 Dual Acting Receptor Antagonist (DARA)

  3. Slide 3: Dual Acting Receptor Antagonist - DARA

    Slide 3: Dual Acting Receptor Antagonist - DARA

    Dual Acting Receptor Antagonist - DARA Antagonist at the AT1 and ETA receptors Simultaneously blocks the actions of ET-1 and A II Multiple potential clinical indications Potential first-in-class compound PS433540 S N H O O O N Me Me N N O Me O Me

  4. Slide 4: Clinical and Preclinical Rationale

    Slide 4: Clinical and Preclinical Rationale

    Clinical and Preclinical Rationale A II and ET-1 Vasoconstriction Tissue proliferation/fibrosis Inflammation Preclinical Data: ETA + AT1 ERAs additive/synergistic with ARBs or ACEIs in rodent, canine and porcine models of hypertension, heart failure and kidney disease Clinical Data: ETA + AT1 Additi

  5. Slide 5: Phase 1 Development - Update

    Slide 5: Phase 1 Development - Update

    Phase 1 Development - Update Completed AUC 20% Cmax 50% Effect of food on absorption Food effect -007 Completed Capsule and powder in bottle similar pk profile Compare bioavailability of solution vs capsule Comparative bioavailability -004 Completed 250 and 500 mg dose complete AII blockade for 24 h

  6. Slide 6: PK and Safety Profile in SAD study

    Slide 6: PK and Safety Profile in SAD study

    PK and Safety Profile in SAD study Protocol Outline 48 normal volunteers Placebo controlled 6 dose levels from 20 to 1000 mg) (20, 50,100, 250, 500,1000) Blood and urine collection Comprehensive clinical and laboratory analyses Top Line Results Pharmacokinetics Exposure increased with increased dose

  7. Slide 7: AII Challenge Study Results

    Slide 7: AII Challenge Study Results

    AII Challenge Study Results Background Angiotensin challenge studies have been used to demonstrate the ability of ARBs to block the effects of angiotensin on blood pressure A positive result is an indicator for efficacy in hypertension Methods 17 subjects completed this study Each receiving placebo,

  8. Slide 8: Results of Food Effect Study

    Slide 8: Results of Food Effect Study

    Results of Food Effect Study No clinically relevant differences in PK profile Study AAI-US-545 Least-square Mean PS433540 Plasma Concentrations (N=12) PS433540 Plasma Concentration (ng/mL) Hours From Dosing STUDY AAI-US-545 LEAST-SQUARES MEAN PS433540 PLASMA CONCENTRATIONS (N=12) 0 1000 2000 3000 40

  9. Slide 9: Phase 2 Development

    Slide 9: Phase 2 Development

    Phase 2 Development Phase 2b -006 Phase 2a -008 Study On schedule Start 1H08 12-week study. Placebo controlled. DB randomized, active controlled. Approximately 400 subjects; 3 doses Dose related efficacy and safety Comparative efficacy vs irbesartan Study Started Short-term (4-week) placebo controll

  10. Slide 10: PS178990 Selective Androgen Receptor Modulators (SARM)

    Slide 10: PS178990 Selective Androgen Receptor Modulators (SARM)

    PS178990 Selective Androgen Receptor Modulators (SARM)

  11. Slide 11: Androgen Receptor Function

    Slide 11: Androgen Receptor Function

    Androgen Receptor Function The Androgen Receptor: Is a member of the Nuclear Hormone Receptor family of ligand dependent transcription factors Mediates cell growth & differentiation in AR responsive tissues Androgens are hormones that play critical roles in health, regulating not only the reproducti

  12. Slide 12: Potential Benefits of Androgens

    Slide 12: Potential Benefits of Androgens

    7 Muscle Mass 7 Muscle Strength Potential Benefits + Cognition tT Energy T Libido A 7 Bone Formation | Bone Resorption 7 Bone Density & Strength

  13. Slide 13: Effects To Be Minimized

    Slide 13: Effects To Be Minimized

    Effects To Be Minimized — Pharmacopeia Effects of Androgens Potential Risks Bone Marrow T Red Cell Production + Sebum Production + Hair Growth + Prostate Mass 1 Cell Turnover

  14. Slide 14: SARM: Medical Need

    Slide 14: SARM: Medical Need

    SARM: Medical Need Muscle Selective Androgen Receptor Modulators (SARMs) that: are orally active, non-steroidal small molecules improve muscle mass and function have minimal effects on the prostate, gonadotropin levels, hematopoiesis are not hepatotoxic in therapeutic range

  15. Slide 15: Overview PS178990

    Slide 15: Overview PS178990

    Overview PS178990 PS178990 is a Phase 1 Selective Androgen Receptor Modulator (SARM) Potential indications: post-surgical recovery, burn recovery, kidney disease wasting and cancer- and AIDS-cachexia minimize loss of muscle and bone minimize prostate related safety risk

  16. Slide 16: PS-178990: Potent and Selective SARM

    Slide 16: PS-178990: Potent and Selective SARM

    PS-178990: Potent and Selective SARM Levator -TP Levator-’929 Prostate-TP Prostate-’929 Testosterone ED50 levator = 210 mg/kg ED50 prostate = 420 mg/kg selectivity = 2-fold PS-178990 ED50 levator = 0.9 mg/kg ED50 prostate = 141 mg/kg selectivity = 160-fold TP = testosterone propionate Castrated Rat

  17. Slide 17: Sex Hormone Feedback Control in Man

    Slide 17: Sex Hormone Feedback Control in Man

    GnRH (hypothalamus) Testosterone (testis) LH, FSH (pituitary) Testosterone negative feedback hypothalamic - pituitary - gonadal axis Sex Hormone Feedback Control in Man

  18. Slide 18: PS178990 Selectivity in Castrated Rat Model

    Slide 18: PS178990 Selectivity in Castrated Rat Model

    Testosterone ED50 levator = 210 mg/kg ID50 LH = 260 mg/kg selectivity = 1-fold PS178990 ED50 levator = 0.9 mg/kg ID50 LH = 8 mg/kg selectivity = 9-fold 1.0e-006 1.0e-005 1.0e-004 0.001 0.01 0.1 1 10 100 -100 -80 -60 -40 -20 0 20 Testosterone PS178990 Dose (mg/kg) Percent Intact Control LH Suppressio

  19. Slide 19: Single Ascending Dose – PS178990

    Slide 19: Single Ascending Dose – PS178990

    0.01 0.1 1 10 100 0 8 16 24 32 40 48 Time (h) PS178990 Plasma Conc (ng/mL) 0.003 mg (N=6) 0.01 mg (N=6) 0.03 mg 0.1 mg (N=6) 0.3 mg (N=6) 1 mg (N=6) 2 mg (N=6) parent detection limit in plasma = 0.025 ng/mL T1/2 = 8-14 hours Single Ascending Dose – PS178990 PS178990 Plasma Concentration Time Profile

  20. Slide 20: FSH and LH Concentration – PS178990

    Slide 20: FSH and LH Concentration – PS178990

    Mean % Change from Baseline Time (h) 0 8 16 24 32 40 48 -40 -30 -20 -10 0 10 20 30 40 PBO (N= 15) 0.03 mg (N=6) 0.1 mg (N=6) 0.3 mg (N=6) 1 mg (N=6) 2 mg (N=6) 5 mg (N=3) Time (h) 0 8 16 24 32 40 48 -100 -80 -60 -40 -20 0 20 40 60 80 100 FSH LH FSH and LH Concentration – PS178990 Projected efficacio

  21. Slide 21: Summary of PS-178990 SARM Profile

    Slide 21: Summary of PS-178990 SARM Profile

    Summary of PS-178990 SARM Profile Potent and Selective Androgen 230 x more potent on muscle than T in rats 160 x more active on muscle than prostate in rats No interaction with other nuclear hormone receptors No signal transduction through SHBG Development Potential Good preclinical pharmaceutical a

  22. Slide 22: SARM - Development Plans

    Slide 22: SARM - Development Plans

    SARM - Development Plans Complete technology transfer – 1Q-08 Qualify API – 6 kg available Initiate Multiple Ascending Dose study – 1H-08 Initiate Phase 2 – 1H-09 Effects on lean body mass, muscle strength and prostate size in relatively healthy elderly men

Source: SEC EDGAR · 8-K filed Nov 14, 2007

More decks from Pharmacopeia Inc